Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

Two Additions to Standard of Care in Prostate Cancer May Improve Outcomes

The addition of abiraterone acetate and prednisone (AAP) or docetaxel and prednisone (DocP) to standard of care (SOC) may improve survival outcomes in patients with high-risk prostate cancer (PCa) initiating long-term androgen deprivation therapy, according to data presented at the European Society of Medical Oncology (ESMO) 2017 Congress in Spain

Read more.

source: Cancer Therapy Advisor